Positron Emission Tomography (PET) and Computer Tomography (CT) scanners are combined to provide utmost diagnostic capabilities to patients. This combination produces a highly sensitive imaging and detects diseases at an early stage that are often undetected by CT alone or by other imaging procedures such as magnetic resonance imaging (MRI). The CT component of the system adds anatomical information to the PET scan and provides accurate information on the location of disease in the body. These equipment are used for diagnosis of different types of cancers, such as colorectal cancers and lymphomas, as well as some neurological and cardiac conditions.
Get Exclusive Discount at: @
Market Dynamics
Increasing prevalence of various chronic diseases such as different types of cancer, heart conditions, and neurological disorders demand disease diagnosis at early stage. For instance, in 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the U.S. It is a powerful tool for determining and diagnosing the stage of many cancer types, including breast, brain, cervical, colorectal, esophageal, head and neck, lung, lymphoma, melanoma, pancreatic, and thyroid cancers. PET/CT is also finding potential value for radiation therapy planning. With recent advances in intensity-modulated radiation therapy, it is possible to treat tumors while reducing radiation doses to non-targeted organs when compared with traditional techniques.
PET-CT scans can also detect early onset of neurological disorders such as Alzheimer’s disease. It is frequently used to identify areas of the brain causing epileptic seizures. However, PET-CT scan is not recommended for all patients due to harmful radiation that causes side effects to the body. For instance, it is not suitable for pregnant women, as the radiation could harm the baby.
Key features of the study:
This report provides in-depth analysis of the PET-CT scanner device market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period 2018 – 2026, considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global PET-CT scanner device market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include General Electric Co., Hitachi, Ltd., Mediso Ltd., Koninklijke Philips N.V., PerkinElmer, Inc., Positron Corporation, Siemens AG, Shimadzu Corporation, Toshiba Corporation, and Yangzhou Kindsway Biotech Co. Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global PET-CT scanner device market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global PET-CT Scanner Device Market, By Detector Type:
FluroDeoxyGlucose (FDG)
62CU ATSM
FMISO
Gallium
Thallium
Others
Global PET-CT Scanner Device Market, By Setting:
Fixed
Mobile
Global PET-CT Scanner Device Market, By Application:
Cardiology
Oncology
Neurology
Others
Global PET-CT Scanner Device Market, By End User:
Hospitals
Diagnostic Centers
Research Institutes
Global PET-CT Scanner Device Market, By Region:
North America
By Country:
U.S.
Canada
By Detector Type:
FluroDeoxyGlucose (FDG)
62CU ATSM
FMISO
Gallium
Thallium
Others
By Setting:
Fixed
Portable
By Application:
Cardiology
Neurology
Oncology
Others
By End User:
Hospitals
Diagnostic Centers
Research Institutes
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Detector Type:
FluroDeoxyGlucose (FDG)
62CU ATSM
FMISO
Gallium
Thallium
Others
By Setting:
Fixed
Portable
By Application:
Cardiology
Neurology
Oncology
Others
By End User:
Hospitals
Diagnostic Centers
Research Institutes
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Detector Type:
FluroDeoxyGlucose (FDG)
62CU ATSM
FMISO
Gallium
Thallium
Others
By Setting:
Fixed
Portable
By Application:
Cardiology
Neurology
Oncology
Others
By End User:
Hospitals
Diagnostic Centers
Research Institutes
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Detector Type:
FluroDeoxyGlucose (FDG)
62CU ATSM
FMISO
Gallium
Thallium
Others
By Setting:
Fixed
Portable
By Application:
Cardiology
Neurology
Oncology
Others
By End User:
Hospitals
Diagnostic Centers
Research Institutes
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Detector Type:
FluroDeoxyGlucose (FDG)
62CU ATSM
FMISO
Gallium
Thallium
Others
By Setting:
Fixed
Portable
By Application:
Cardiology
Neurology
Oncology
Others
By End User:
Hospitals
Diagnostic Centers
Research Institutes
Africa
By Country:
South Africa
Central Africa
North Africa
By Detector Type:
FluroDeoxyGlucose (FDG)
62CU ATSM
FMISO
Gallium
Thallium
Others
By Setting:
Fixed
Portable
By Application:
Cardiology
Neurology
Oncology
Others
By End User:
Hospitals
Diagnostic Centers
Research Institutes
Company Profiles
General Electric Co.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Hitachi, Ltd.
Mediso Ltd.
Koninklijke Philips N.V.
PerkinElmer, Inc.
Positron Corporation
Siemens AG
Shimadzu Corporation
Toshiba Corporation
Yangzhou Kindsway Biotech Co. Ltd.
Get Exclusive Discount at: @
“*” marked represents similar segmentation in other categories in the respective section.
Industry Forecast Research 